The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Luca Boni, Alessandro Inno et al.|PLoS ONE|2015Cited by 13
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective StudySara Gagno, Giuseppe Toffoli, Mario D’Andrea et al.|Clinical Breast Cancer|2018Cited by 10
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registryLaia Garrigós, Maria Belen Delany, Sònia Pernas et al.|Therapeutic Advances in Medical Oncology|2021Cited by 7
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Luca Boni, Alessandro Inno et al.|PLoS ONE|2015Cited by 3
Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience.Sandro Barni, Elena Collovà, I. Vallini et al.|Journal of Clinical Oncology|2013Cited by 0